Cellular and molecular mechanisms of non-insulin dependent diabetes mellitus

Journal of Investigative Medicine

Volumn 44, Issue 8, 1996, Pages 413-428

  Kruszynska, Yolanta T ^a   Olefsky, Jerrold M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1; GLUCOSE; INORGANIC PYROPHOSPHATASE; INSULIN; MEMBRANE PROTEIN; PHOSPHODIESTERASE; RAS PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

BIOSYNTHESIS; BLOOD; DIET RESTRICTION; EATING; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SECRETION; SIGNAL TRANSDUCTION;

DIABETES MELLITUS, TYPE 2; EATING; FASTING; GLUCOSE; HUMANS; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; MEMBRANE GLYCOPROTEINS; PHOSPHORIC DIESTER HYDROLASES; PYROPHOSPHATASES; RAS PROTEINS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030253348     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (133)

1. Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennett PH, Bogardus C. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993;329:1988-92.
2. Vaag A, Henriksen JE, Madsbad S, Holm N, Beck-Nielsen H. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. J Clin Invest 1995;95:690-8.
3. Taylor SI, Accili D, Imai Y. Insulin resistance or insulin deficiency: which is the primary cause of NIDDM? Diabetes 1994;43:735-40.
4. Eriksson J, Franssila-Kallunki A, Ekstrand A, Saloranta C, Widen E, Schalin C, Groop L. Early metabolic defects in persons at increased risk for non-insulin dependent diabetes mellitus. N Engl J Med 1989;321:337-43.
5. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of Type II diabetes in the offspring of diabetic parents. Ann Intern Med 1990;13:909-15.
6. Pimenta W, Korytkowski M, Mitrakou A, Jenssen T, Yki-Jarvinen H, Evron W, Dailey G, Gerich J. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM: evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA 1995;273:1855-61.
7. O'Rahilly S, Turner RC, Matthews DR. Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. N Engl J Med 1988;318:1225-30.
8. Vadheim CM, Rotter JI. Genetics of diabetes mellitus. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P. eds. International textbook of diabetes mellitus. Chichester: John Wiley & Sons Ltd, 1992:31-98.
9. Gottesman I, Mandarino LJ, Gerich J. Estimation and kinetic analysis of insulin independent glucose uptake in human subjects. Am J Physiol 1983;244:E632-5.
10. Baron AD, Kolterman OG, Bell J, Mandarino LJ, Olefsky JM. Rates of noninsulin-mediated glucose uptake are elevated in Type II diabetic subjects. J Clin Invest 1985;76:1782-8.
11. Eastman RC, Carson RE, Gordon MR, Berg GW, Lillioja S, Larson SM, Roth J, et al. Brain glucose metabolism in non-insulin-dependent diabetes mellitus: a study in Pima Indians using positron emission tomography during hyperinsulinemia with euglycemic clamp. J Clin Endocrinol Metab 1990;71:1602-10.
12. Gerich JE, Mitrakou A, Kelley D, Mandarino L, Nurjhan N, Reilly J, Jenssen T, Veneman T, Consoli A. Contribution of impaired muscle glucose clearance to reduced postabsorptive systemic glucose clearance in NIDDM. Diabetes 1990;39:211-6.
13. Andres R, Cader G, Zierler KL. The quantitatively minor role of carbohydrate in oxidative metabolism by skeletal muscle in intact man in the basal state. Measurements of oxygen and glucose uptake and carbon dioxide and lactate production in the forearm. J Clin Invest 1956;35:671-82.
14. Ferrannini E, Groop LC. Hepatic glucose production in insulin-resistant states. Diabetes Metab Rev 1989;5:711-25.
15. Brooks D, Gibbs J, Sharp P, Herold S, Turton D, Luthra S, Kohner E, Bloom S, Jones T. Regional cerebral glucose transport in insulin-dependent diabetic patients studied using [11C]-3-O-methyl-D-glucose and positron emission tomography. J Cereb Blood Flow Metab 1986;6:240-4.
16. Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI. Increased rate of gluconeogenesis in Type II diabetes mellitus: a 13C nuclear magnetic resonance study. J Clin Invest 1992;90:1323-7.
17. Nurjhan N, Consoli A, Gerich JE. Increased lipolysis and its consequences on gluconeogenesis in non-insulin-dependent diabetes mellitus. J Clin Invest 1992;89:169-75.
18. Puhakainen I, Koivisto VA, Yki-Jarvinen H. Lipolysis and gluconeogenesis from glycerol are increased in patients with non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1992;75:789-94.
19. Consoli A, Nurjhan N, Reilly JJ, Bier DM, Gerich JE. Mechanism of increased gluconeogenesis in non-insulin-dependent diabetes mellitus: role of alterations in systemic, hepatic, and muscle lactate and alanine metabolism. J Clin Invest 1990;86:2038-45.
20. Firth R, Bell P, Rizza R. Insulin action in non-insulin-dependent diabetes mellitus: the relationship between hepatic and extrahepatic insulin resistance and obesity. Metabolism 1987;36:1091-5.
21. Groop LC, Bonadonna RC, Del Prato S, Ratheiser K, Zyck K, Ferrannini E, DeFronzo RA. Glucose and free fatty acid metabolism in non-insulin dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 1989;84:205-13.
22. Baron AD, Schaeffer L, Shragg P, Kolterman OG. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 1987;36:274-83.
23. Williamson J, Kreisberg R, Felts P. Mechanism for the stimulation of gluconeogenesis by fatty acids in perfused rat liver. Proc Natl Acad Sci USA 1966;56:247-54.
24. Agius L, Alberti KGMM. Regulation of flux through pyruvate dehydrogenase and pyruvate carboxylase in rat hepatocytes. Effects of fatty acids and glucagon. Eur J Biochem 1985;152:699-707.
25. Taskinen MR, Bogardus C, Kennedy A, Howard BV. Multiple disturbances of free fatty acid metabolism in non-insulin-dependent diabetes. Effect of oral hypoglycemic therapy. J Clin Invest 1985;76:637-44.
26. Avogaro A, Valerio A, Gnudi L, Maran A, Zolli M, Duner E, Riccio A, Del Prato S, Tiengo A, Nosadini R. Ketone body metabolism in NIDDM. Effect of sulfonylurea treatment. Diabetes 1992;41:968-74.
27. Vaag A, Damsbo P, Hother-Nielsen O, Beck-Nielsen H. Hyperglycemia compensates for the defects in insulin-mediated glucose metabolism and in the activation of glycogen synthase in the skeletal muscle of patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992;35;80-8.
28. Mitrakou A, Kelley D, Veneman T, Jenssen T, Pangburn T, Reilly J, Gerich J. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 1990;39:1381-90.
29. DeFronzo RA, Gunnarsson R, Bjorkman O, Olsson M, Wahren J. Effects of insulin on peripheral and splanchnic glucose metabolism in non-insulin-dependent (Type II) diabetes mellitus. J Clin Invest 1985;76: 149-55.
30. Kelley DE, Mandarino LJ. Hyperglycemia normalizes insulin-stimulated skeletal muscle glucose oxidation and storage in non-insulin-dependent diabetes mellitus. J Clin Invest 1990;86:1999-2007.
31. Ferrannini E, Bjorkman O, Reichard GA, Pilo A, Olsson M, Wahren J, DeFronzo RA. The disposal of an oral glucose load in healthy subjects: a quantitative study. Diabetes 1985;34:580-8.
32. Kruszynska YT, Meyer-Alber A, Darakhshan F, Home PD, McIntyre N. Metabolic handling of orally administered glucose in cirrhosis. J Clin Invest 1993;91:1057-66.
33. Kelley D, Mitrakou A, Marsh H, Schwenk F, Benn J, Sonnenberg G, Arcangeli M, Aoki T, Sorensen J, Berger M, Sonksen P, Gerich J. Skeletal muscle glycolysis, oxidation, find storage of an oral glucose load. J Clin Invest 1988;81:1563-71.
34. Radziuk J, McDonald TJ, Rubenstein D, Dapre J. Initial splanchnic extraction of ingested glucose in normal man. Metabolism 1978;27:657-79.
35. Niewoehner CB, Nuttall FQ. Relationship of hepatic glucose uptake to intrahepatic glucose concentration in fasted rats after glucose load. Diabetes 1988;37:1559-66.
36. Wals PA, Katz J. A concentration gradient of glucose from liver to plasma. Metabolism 1993;42:1492-6.
37. Pagliassoti MJ, Holste LC, Moore MC, Neal DW, Cherrington AD. Comparison of the time courses of insulin and the portal signal on hepatic glucose and glycogen metabolism in the conscious dog. J Clin Invest 1996;97:81-91.
38. Firth RG, Bell PM, Marsh HM, Hansen I, Rizza RA. Postprandial hyperglycemia in patients with non-insulin-dependent diabetes mellitus. Role of hepatic and extrahepatic tissues. J Clin Invest 1986;77:1525-32.
39. Ludvik B, Nolan JJ, Baloga J, Joyce M, Bell JM, Olefsky JM. A noninvasive method to measure splanchnic glucose uptake after oral glucose administration. J Clin Invest 1995;95:2232-8.
40. Thorburn AW, Gumbiner B, Bulacan F, Brechtel G, Henry RR. Multiple defects in muscle glycogen synthase activity contribute to reduced glycogen synthesis in non-insulin-dependent diabetes mellitus. J Clin Invest 1991;87:489-95.
41. Boden G, Ray TK, Smith RH, Owen OE. Carbohydrate oxidation and storage in obese non-insulin-dependent diabetic patients. Effects of improving glycemic control. Diabetes 1983;32:982-7.
42. Kruszynska YT. The role of fatty acid metabolism in the hypertriglyceridaemia and insulin resistance of Type 2 (non-insulin-dependent) diabetes. In: Marshall SM, Home PD, Rizza RA, eds. The diabetes annual. Amsterdam: Elsevier Science Publishers, 1995;9:107-39.
43. Rebrin K, Steil GM, Getty L, Bergman RN. Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin. Diabetes 1995;44:1038-45.
44. Boden G, Chen X, White JV, Rossetti L. Mechanisms of fatty-acid inhibition of glucose uptake. J Clin Invest 1994;93:2438-46.
45. Polonsky KS. The b-cell in diabetes: from molecular genetics to clinical research. Diabetes 1995;44:705-717.
46. O'Meara NM, Sturis J, Van Cauter E, Polonsky KS. Lack of control by glucose of ultradian insulin secretory oscillations in impaired glucose tolerance and non-insulin-dependent diabetes mellitus. J Clin Invest 1993;92:262-71.
47. Wallum BJ, Kahn SE, McCulloch DK, Porte D. Insulin secretion in the normal and diabetic human. In: Alberti KGMM, DeFronzo RA, Keen H, Zimmet P, eds. International textbook of diabetes mellitus. Chichester: John Wiley & Sons Ltd, 1992:285-301.
48. Yudkin JS: Circulating proinsulin-like molecules. J Diabetes Complications 1993;7:113-23.
49. Temple RC, Carrington CA, Luzio SD, Owens DR, Schneider AE, Sobey WJ, Hales CN. Insulin deficiency in non-insulin-dependent diabetes. Lancet 1989;1:293-5.
50. Reaven GM, Bernstein R, Davis B, Olefsky JM. Nonketotic diabetes mellitus: insulin deficiency or insulin resistance? Am J Med 1976;60:80-8.
51. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW. Physiological importance of deficiency in early prandial insulin secretion in non-insulin dependent diabetes. Diabetes 1988;37:736-44.
52. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, Frank BH, Galloway JA, Van Cauter E. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1988;318:1231-9.
53. Garvey WT, Olefsky JM, Rubenstein AH, Kolterman OG. Day-long integrated serum insulin and C-peptide profiles in patients with NIDDM. Correlation with urinary C-peptide excretion. Diabetes 1988;37:590-9.
54. Garvey WT, Olefsky JM, Griffin J, Hammon R, Kolterman OG. The effects of insulin treatment on insulin secretion and action in Type II diabetes mellitus. Diabetes 1985;34:222-34.
55. Kolterman OG, Gray RS, Shapiro G, Scarlett JA, Griffin J, Olefsky JM. The acute and chronic effects of sulfonylurea therapy in Type D diabetics. Diabetes 1984;33:346-54.
56. Henry RR, Wallace P, Olefsky JM. The effects of weight loss on the mechanisms of hyperglycemia in obese noninsulin-dependent diabetes mellitus. Diabetes 1986;35:990-8.
57. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications. Diabetes 1995;44:863-70.
58. Milburn JL, Hirose H, Lee YH, Nagasawa Y, Ogawa A et al. Pancreatic β-cells in obesity: evidence for induction of functional, morphologic, and metabolic abnormalities by increased long chain fatty acids. J Biol Chem 1995;270:1295-9.
59. Becker TC, BeltrandelRio H, Noel RJ, Johnson JH, Newgard CB. Overexpression of hexokinase I in isolated islets of langerhans via recombinant adenovirus: enhancement of glucose metabolism and insulin secretion at basal but not stimulatory glucose levels. J Biol Chem 1994;269:21234-8.
60. Hirose H, Lee YH, Inman LR, Nagasawa Y, Johnson JH, Unger RH. Defective fatty acid-mediated β-cell compensation in Zucker diabetic rats: pathogenic implications for obesity-dependent diabetes. J Biol Chem 1996;271:5633-7.
61. Kolterman OG, Gray RS, Griffin J, Burstein P, Insel J. Receptor and postreceptor defects contribute to the insulin resistance in non-insulin dependent diabetes mellitus. J Clin Invest 1981;68:957-69.
62. Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, Shulman RG. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med 1990;322:223-8.
63. Seely BL, Olefsky JM. Potential cellular and genetic mechanisms for insulin resistance in common disorders of obesity and diabetes. In: Moller D, ed. Insulin resistance and its clinical disorders. Chichester: John Wiley & Sons, Ltd, 1993:187-252.
64. Cheatham B, Kahn CR. Insulin action and the insulin signaling network. Endocr Rev 1995;16: 117-142.
65. Wilden PA, Siddle K, Haring H, Backer JM, White ME, Kahn CR. The role of insulin receptor kinase domain autophosphorylation in receptor mediated activities. J Biol Chem 1992;267: 13719-27.
66. McClain DA, Maegawa H, Lee J, Dull TJ, Ulrich A, Olefsky JM. A mutant insulin receptor with defective tyrosine kinase displays no biologic activity and does not undergo endocytosis. J Biol Chem 1987;262:14663-71.
67. Morgan DO, Ho L, Korn LJ, Roth RA. Insulin action is blocked by a monoclonal antibody that inhibits the insulin receptor kinase. Proc Natl Acad Sci USA 1986;83:328-32.
68. Taylor SI, Cama A, Accili D, Barbetti F, Quon MJ, Sierra M, Suzuki Y. Mutations in the insulin receptor gene. Endocr Rev 1992;13:566-95.
69. Sun XJ, Rothenberg P, Kahn CR, Backer JM, Araki E, Wilden PA et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 1991;352:73-7.
70. Skolnik EY, Lee CH, Batzer A, Vicentini LM, Zhou M, Daly R, Myers MJ, Backer JM, Ullrich A, White MF, Schlessinger J. The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS 1 and Shc: implications for insulin control of ras signaling. EMBO J 1993;12:1929-36.
71. Fink RI, Wallace P, Brechtel G, Olefsky JM. Evidence that glucose transport is rate-limiting for in vivo glucose uptake. Metabolism 1992;41:897-902.
72. Shepherd PR, Kahn BB. Cellular defects in glucose transport: lessons from animal models and implications for human insulin resistance. In: Moller DE, ed. Insulin resistance. Chichester: John Wiley & Sons Ltd. 1993;253-300.
73. Kelley DE, Mintun MA, Watkins SC, Simoneau J-A, Jadali F, Fredrickson A, Beattie J, Theriault R. The effect of non-insulin dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. J Clin Invest 1996;97:2705-13.
74. Guma A, Zierath JR, Wallberg-Henriksson H, Klip A. Insulin induces translocation of Glut-4 glucose transporters in human skeletal muscle. Am J Physiol 1995;268:E613-22.
75. Bonadonna RC, Del Prato S, Saccomani MP, Bonora E, Gulli G, Ferrannini E, Bier D, Cobelli C, DeFronzo RA. Transmembrane glucose transport in skeletal muscle of patients with non-insulin-dependent diabetes. J Clin Invest 1993;92:486-94.
76. Garvey WT, Maianu L, Huecksteadt TP, Birnbaum MJ, Molina JM, Ciaraldi TP. Pretranslational suppression of a glucose transporter protein causes cellular insulin resistance in non-insulin-dependent diabetes mellitus and obesity. J Clin Invest 1991;87:1072-81.
77. Kashiwagi A, Verso MA, Andrews J, Vasquez B, Reaven G, Foley JE. In vitro insulin resistance of human adipocytes isolated from subjects with noninsulin-dependent diabetes mellitus. J Clin Invest 1983;72:1246-54.
78. Bak JF, Schmitz O, Sorensen NS, Pedersen O. Postreceptor effects of sulfonylurea on skeletal muscle glycogen synthase activity in type II diabetic patients. Diabetes 1989;38:1343-50.
79. Kolterman OG, Scarlett JA, Olefsky JM. Insulin resistance in non-insulin-dependent. Type II diabetes mellitus. J Clin Endocrinol Metab 1982;11:363-88.
80. Kobayashi M, Olefsky JM. Effects of streptozotocin-induced diabetes on insulin binding, glucose transport, and intracellular glucose metabolism in isolated rat adipocytes. Diabetes 1979;28:87-95.
81. Freidenberg GR, Henry RR, Klein HH, Reichart DR, Olefsky JM. Decreased kinase activity of insulin receptors from adipocytes of non-insulin dependent diabetic subjects. J Clin Invest 1987;79:240-50.
82. Bolinder J, Ostman J, Arner P. Postreceptor defects causing insulin resistance in normoinsulinemic non-insulin-dependent diabetes mellitus. Diabetes 1982;31:911-6.
83. Nolan JJ, Freidenberg G, Henry R, Reichart D, Olefsky JM. Role of human skeletal muscle insulin receptor kinase in the in vivo insulin resistance of noninsulin-dependent diabetes mellitus and obesity. J Clin Endocrinol Metab 1993;78:471-7.
84. Thies RS, Molina JM, Ciaraldi TP, Freidenberg GR, Olefsky JM. Insulin-receptor autophosphorylation and endogenous substrate phosphorylation in human adipocytes from control, obese, and NIDDM subjects. Diabetes 1990;39:250-9.
85. Comi RJ, Grunberger G, Gorden P. Relationship of insulin binding and insulin stimulated tyrosine kinase activity is altered in type II diabetes. J Clin Invest 1987;79:453-62.
86. Brillon DR, Freidenberg GR, Henry RR, Olefsky JM: Mechanism of defective insulin receptor kinase activity in NIDDM: Evidence for two receptor populations. Diabetes 1989;38:397-403.
87. Freidenberg GR, Reichart D, Olefsky JM, Henry RR. Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin dependent diabetes mellitus: effects of weight loss. J Clin Invest 1988;82:1398-406.
88. Pedersen O, Hjollund E. Insulin receptor binding to fat and blood cells and insulin action in fat cells from insulin-dependent diabetics. Diabetes 1982;31:706-715.
89. Yki-Jarvinen H, Kubo K, Zawadzki J, Lillioja S, Young A, Abbott W, Foley JE. Dissociation of in vitro sensitivities of glucose transport and antilipolysis to insulin in NIDDM. Am J Physiol 1987;253:E300-4.
90. Freidman JE, Dohm GL, Leggett-Frazier N et al. Restoration of insulin-responsiveness in skeletal muscle of morbidly obese patients after weight loss: effect on muscle glucose transport and glucose transporter Glut 4. J Clin Invest 1992;89:701-5.
91. Garvey WT, Kolterman OG. Correlations between in vivo and in vitro actions of insulin in obesity and diabetes. Diabetes Metab Rev 1988;4:543-70.
92. Eriksson J, Koranyi L, Bourey R, Schalin-Jantti C, Widen E, Mueckler M, Permutt AM, Groop LC. Insulin resistance in Type 2 (non-insulin-dependent) diabetic patients and their relatives is not associated with a defect in the expression of the insulin-responsive glucose transporter (GLUT-4) gene in human skeletal muscle. Diabetologia 1992;35:143-7.
93. Kahn BB, Rosen AS, Bak JF, et al. Expression of Glut 1 and Glut 4 glucose transporters in skeletal muscle of humans with insulin dependent diabetes mellitus: Regulatory effects of metabolic factors. J Clin Endocrinol Metab 1992;74:1101-9.
94. Yki-Jarvinen H. Glucose toxicity. Endocr Rev 1992;13:415-31.
95. Chen KS, Heydrick S, Kurowski T, Ruderman NB. Diacylglycerol-protein kinase C signaling in skeletal muscle: a possible link to insulin resistance. Trans Assoc Amer Physicians 1991;104:206-12.
96. Muller HK, Kellerer M, Ermel B, Muhlhofer A, Obermaier-Kusser B, Vogt B, Haring HU. Prevention by protein kinase C inhibitors of glucose-induced insulin receptor tyrosine kinase resistance in rat fat cells. Diabetes 1991;40:1440-8.
97. Kellerer M, Coghlan M, Capp E, Muhlhofer A, Kroder G, Mosthaf L, Galente P, Siddle K, Haring HU. Mechanism of insulin receptor kinase inhibition in non-insulin-dependent diabetes mellitus patients. Phosphorylation of serine 1327 or threonine 1348 is unaltered. J Clin Invest 1995;96:6-11.
98. Henriksen EJ, Rodnick KJ, Holloszy JO. Activation of glucose transport in skeletal muscle by phospholipase C and phorbol ester. J Biol Chem 1989;264:21536-43.
99. Blackmore PF, Strickland WG, Bocckino SB, Exton JH. Phosphorylation of glycogen synthase by protein kinase C. Biochem J 1986;237:235-42.
100. Chin JE, Dickens M, Tavare JM, Roth RA. Overexpression of protein kinase C isoenzymes α, βI, γ, and ∈ in cells overexpressing the insulin receptor: effects on receptor phosphorylation and signaling. J Biol Chem 1993;268:6338-47.
101. Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating desensitization of the glucose transport system: role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem 1992;266:4706-12.
102. Rossetti L, Hawkins M, Chen W, Gindi J, Barzilai N. In vivo glucosamine infusion induces insulin resistance in normoglycemic but not in hyperglycemic conscious rats. J Clin Invest 1995;96:132-40.
103. Yki-Jarvinen H, Daniels MC, Makimattila S, Virkamaki A, DeFronzo RA. Glutamine: fructose-6-phosphate amidotransferase (GFA) activity in skeletal muscle of patients with IDDM and NIDDM. Diabetes 1995;44(1 Suppl):16A.
104. Robinson KA, Sens DA, Buse MG. Pre-exposure to glucosamine induces insulin resistance of glucose transport and glycogen synthesis in isolated rat skeletal muscles: study of mechanisms in muscle and in rat-1 fibroblasts overexpressing the human insulin receptor. Diabetes 1993;42:1333-46.
105. Baron AD, Zhu J-S et al. Glucosamine (Glmn) induces insulin resistance (IR) in vivo by affecting glut 4 translocation in skeletal muscle: implications for glucose toxicity. Diabetes 1995;44(1 suppl):15A.
106. Garvey WT, Olefsky JM, Mathei S, Marshall S. Glucose and insulin co-regulate the glucose transport system in primary cultured adipocytes. J Biol Chem 1987;262:189-97.
107. Hotamisligil SG, Spiegelman BM. Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes 43:1271-8.
108. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 1995;95:2409-15.
109. Hofmann C, Lorenz K, Braithwaite SS, Colca JR, Palazuk BJ, Hotamisligil GS, Spiegelman BM. Altered gene expression for tumor necrosis factor-α and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 1994;134:264-70.
110. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 1992;130:43-52.
111. Sakurai Y, Zhang X, Wolfe RR. Short-term effects of tumor necrosis factor on energy and substrate metabolism in dogs. J Clin Invest 1993;91:2437-45.
112. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes: central role of tumor necrosis factor-α. J Clin Invest 1994;94:1543-9.
113. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α and obesity-induced insulin resistance. Science 1996;271:665-8.
114. Evans, DA, Jacobs DO, Wilmore DW. Tumor necrosis factor enhances glucose uptake by peripheral tissues. Am J Physiol 1989;257:R1182-9.
115. Reynet C, Kahn CR. Rad: A member of the ras family overexpressed in muscle of Type II diabetic humans. Science 1993;262:1441-4.
116. Zhu J, Reynet C, Caldwell JS, Kahn CR. Characterization of Rad, a new member of Ras/GTPase superfamily, and its regulation by a unique GTPase-activating protein (GAP)-like activity. J Biol Chem 1995;270:4805-12.
117. Moyers JS, Reynet C, Zhu J, Bilan PJ, Kahn CR. A role for rad as an inhibitor of insulin-stimulated glucose transport. Diabetes 1995;44(1 Suppl):302.
118. Patti ME, Vestergaard H, Reynet C, Moyers J, Pedersen O, Kahn CR. Rad expression in human skeletal muscle correlates inversely with insulin-stimulated glucose disposal [abstract]. J Investig Med 1995;43(2 Suppl):322A.
119. Yarnall DP, Lenhard JM, Hamacher L, Marshall S, Rumberger JM, Maianu L, Garvey WT, Burns DK. Rad expression in skeletal muscle of Type II diabetics. Diabetes 1995;44 (1 Suppl):81A.
120. Maddux BA, Sbraccia P, Kumakura S, Sasson S, Youngren J, Fisher A, Spencer S, Grupe A, Henzel W, Stewart TA, Reaven GM, Goldfine ID. Membrance glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus. Nature 1995;373:448-51.
121. Sbraccia P, Goodman PA, Maddux BA, Wong KY, Chen YD-I, Reaven GM, Goldfine ID. Production of inhibitor of insulin-receptor tyrosine kinase in fibroblasts from patients with insulin resistance and NIDDM. Diabetes 1991;40:295-9.
122. Pillay TS, Langlois WJ, Olefsky JM. The genetics of noninsulin-dependent diabetes mellitus. Adv Genet 1995;32:51-98.
123. Almind K, Bjorbaek C, Vestergaard H, Hansen T, Echwald S, Pedersen O. Aminoacid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus. Lancet 1993;342:828-32.
124. Imai Y, Philippe N, Sesti G, Accili D, Taylor SI. Transfection studies of insulin receptor substrate-1 with variant sequences found in patients with non-insulin-dependent diabetes mellitus [abstract]. J Investig Med 1996;44(3 Suppl):259A.
125. Bogardus C, Lillioja S, Stone K, Mott D. Correlation between muscle glycogen synthase activity and in vivo insulin action in man. J Clin Invest 1984;73:1185-90.
126. Bjorbaek C, Vik TA, Echwald SM, Yang P-Y, Vestergaard H, Wang JP, Webb GC et al. Cloning of a human insulin-stimulated protein kinase (ISPK-1) gene and analysis of coding regions and phosphatase-1 genes in muscle from NIDDM patients. Diabetes 1995;44:90-7.
127. Laasko M, Malkki M, Deeb SS. Amino acid substitutions in hexokinase II among patients with NIDDM. Diabetes 1995;44:330-4.
128. Walston J, Silver K, Bogardus C et al. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the β3 adrenergic receptor gene. N Engl J Med 1995;333:343-7.
129. Widen E, Lehto M, Kanninen T, Walston J, Shuldiner AR, Groop LC. Association of a polymorphism in the β3 adrenergic receptor gene with features of insulin resistance syndrome in Finns. N Engl J Med 1995;333:348-51.
130. Permutt MA. Use of DNA polymorphisms for genetic analysis of non-insulin-dependent diabetes mellitus. Baillere's Clin Endocrinol Metab 1991;5:495-526.
131. Prochazka M, Lillioja S, Tait JF, Knowler WC, Mott DM, Spraul M, Bennett PH, Bogardus C. Linkage of chromosomal markers on 4q with a putative gene determining maximal insulin action in Pima Indians. Diabetes 1993;42:514-9.
132. Mitchell BD, Kammerer CM, O'Connell P, Harrison CR, Manire M, Shipman P, Moeyer MP, Stern MP, Frazier ML. Evidence for linkage of postchallenge insulin levels with intestinal fatty acid-binding protein (FABP2) in Mexican-Americans. Diabetes 1995;44:1046-53.
133. Humphreys P, McCarthy M, Tuomilehto J, Tuomilehto-Wolf E, Stratton I, Morgan R, Rees A, Owens D, Stengard J, Nissinen A, Hitman G, Turner RC, O'Rahilly S. Chromosome 4q locus associated with insulin resistance in Pima Indians: studies in three European NIDDM populations. Diabetes 1994;43:800-4.